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Introduction: Bevacizumab, a recombinant humanized monoclonal 
antibody against vascular endothelial growth factor, was approved by 
the US Food and Drug Administration for the treatment of advanced 
non–small-cell lung cancer (NSCLC) in combination with carbo-
platin and paclitaxel. ARIES (Avastin Regimens: Investigation of 
Effectiveness and Safety), a prospective observational cohort study, 
evaluated outcomes in a large, community-based population of 
patients with first-line NSCLC.
Methods: From 2006 to 2009, ARIES enrolled patients with locally 
advanced or metastatic NSCLC who were eligible for bevacizumab, 
excluding those with predominantly squamous histology. Patients 
were required to provide informed consent and to have initiated 
bevacizumab with chemotherapy within 4 months before enrollment. 
There were no protocol-defined treatments or assessments. The dos-
ing of bevacizumab and chemotherapy, and the choice of chemother-
apy regimen, was at the discretion of the treating physician.
Results: ARIES enrolled 1967 patients with first-line NSCLC. At 
study closure, median follow-up was 12.5 months (range, 0.2–65.5). 
Median age was 65 years (range, 31–93), and 252 patients (12.8%) 
identified as never smokers. Median progression-free survival was 
6.6 months (95% confidence interval, 6.3–6.9), and median overall 
survival was 13.0 months (95% confidence interval, 12.2–13.8) with 
first-line bevacizumab plus chemotherapy. Incidences of bevacizumab-
associated adverse events (19.7% overall) were consistent with those in 
randomized controlled trials of bevacizumab in NSCLC.
Conclusion: Results from ARIES demonstrate similar outcomes to 
randomized controlled trials of bevacizumab when added to stan-
dard chemotherapy in a real-world patient population with advanced 
NSCLC.
Key Words: Bevacizumab, Chemotherapy, Non–small-cell lung cancer.
(J Thorac Oncol. 2014;9: 1332–1339)
The addition of bevacizumab to systemic chemotherapy has become a standard of care for the first-line treatment of 
patients with advanced nonsquamous non–small-cell lung can-
cer (NSCLC).1,2 In the pivotal Eastern Cooperative Oncology 
Group 4599 (E4599) trial, bevacizumab in combination with 
paclitaxel + carboplatin was associated with significantly lon-
ger overall survival (OS) and progression-free survival (PFS) 
compared with treatment consisting of paclitaxel + carbopla-
tin alone in patients with previously untreated recurrent or 
advanced NSCLC (stage IIIB or IV).2 As a result, the approval 
by the US Food and Drug Administration for the use of beva-
cizumab in combination with paclitaxel + carboplatin in this 
first-line setting was granted in 2006.3 Investigators in AVAiL 
(Avastin in Lung), a second phase III trial conducted primarily 
in Europe, studied the addition of bevacizumab (7.5 or 15 mg/
kg every 3 weeks) to first-line cisplatin + gemcitabine in 
advanced NSCLC and found significant improvement in PFS, 
but no significant improvement in OS in the bevacizumab-
containing arms.4,5 In E4599 and AVAiL, the use of bevaci-
zumab was associated with commonly occurring, manageable 
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adverse events (AEs), such as proteinuria and hypertension, 
and infrequent, more severe AEs, including bleeding events 
and pulmonary hemorrhage.2,4 The wider applicability of 
these studies was hampered by understandable, but restrictive 
eligibility criteria for participation of subjects.
In wider clinical practice, the use of bevacizumab 
has expanded into other chemotherapy regimens and, more 
importantly, into a broader patient population in which many 
of the exclusion criteria specified in randomized controlled 
trials (RCTs) are not applied.6–8 Under these circumstances, 
phase IV single-arm and observational studies may serve to 
inform the medical community on real-world safety, effec-
tiveness, and usage patterns of bevacizumab. The phase IV 
SAiL (Safety of Avastin in Lung Cancer) study, conducted 
primarily in Europe, enrolled patients with locally advanced 
or metastatic NSCLC who received first-line bevacizumab 
(7.5 mg/kg or 15 mg/kg q3w) in combination with standard-
of-care chemotherapy (the regimen was chosen by the treat-
ing physician).7 Results from the SAiL study supported the 
safety profile of first-line bevacizumab in a less-selected 
patient population. By design, results from such noncom-
parative studies are not directly comparable with RCTs. 
However, they do provide useful information not obtainable 
from RCTs, serving to complement the existing body of 
knowledge.9,10
The ARIES (Avastin Regimens: Investigation of 
Treatment Effects and Safety; NCT00388206) observational 
cohort study (OCS) was initiated in 2006 to evaluate the safety 
and effectiveness of the combination of bevacizumab and 
chemotherapy in patients in the United States with advanced 
NSCLC who are receiving first-line treatment. Here we report 
the final study results from ARIES.
PATIENTS AND METHODS
Study Design and Patient Enrollment
ARIES was a US-based, multicenter, prospective OCS 
that enrolled patients with locally advanced or metastatic 
NSCLC (excluding patients with predominantly squamous 
histology) who were receiving bevacizumab in combina-
tion with first-line chemotherapy. The study was designed 
to have a population of approximately 2000 patients with 
NSCLC. There were four protocol-specified inclusion cri-
teria: (1) signed informed consent, (2) locally advanced 
or metastatic NSCLC, (3) eligibility for bevacizumab as a 
component of intended therapy, and (4) first-line chemo-
therapy with bevacizumab initiated within 4 months before 
study enrollment (allowing patients to enter the study after 
beginning their first-line treatment). Patients with a history 
of brain metastases, on concurrent anticoagulation, with 
Eastern Cooperative Oncology Group performance status 
(ECOG PS) ≥2, or with prior exposure to bevacizumab were 
eligible. Exclusion criteria included any medical condition 
(including mental illness or substance abuse) deemed by the 
investigator to be likely to interfere with a patient’s ability 
to provide informed consent or comply with the treatment 
and follow-up, previous enrollment in a blinded, placebo-
controlled trial of bevacizumab, and predominantly squa-
mous NSCLC histology.
There were no study-specific treatments or assessments. 
The dose and frequency of bevacizumab treatment, the choice 
of chemotherapy regimen (including biologic agents), and the 
method or frequency of clinical assessments were all at the 
discretion of the treating physician. All treatments, including 
bevacizumab, and all supportive care were through commer-
cial supplies or local access-to-care mechanisms. The study 
was approved by a central institutional review board (IRB; 
New England IRB), and by local IRBs if they existed. The 
study was conducted in accordance with the Declaration of 
Helsinki and Good Clinical Practice. All enrolled patients pro-
vided informed consent.
Enrollment began in November 2006. Patients were fol-
lowed until death, study withdrawal, loss to follow-up, or study 
closure (March 31, 2012), whichever occurred first. Patients 
who were lost to follow-up were still followed for death to 
reduce censoring in OS analyses. Sites obtained death infor-
mation from next of kin and then confirmed the date of death 
from national, state, or local death indices. As part of the for-
mal study design, a separate steering committee, comprising 
independent experts and patient advocates representing both 
academic and community practices, was entrusted with over-
seeing the scientific progress and rigor of the study. The steer-
ing committee met at least twice a year with the ARIES core 
team from Genentech, Inc., either in person or by teleconfer-
ence to review data and plan future analyses and publications.
The effectiveness objectives of the study were to 
describe treatment patterns with the use of first-line bevaci-
zumab and to examine the association between the duration 
of the use of bevacizumab and PFS outcome; to explore the 
association between the dose of bevacizumab and clinical 
benefit, as measured by PFS; and to estimate the effectiveness 
of bevacizumab with various chemotherapy regimens. The 
safety objectives included assessing the incidence, potential 
risk factors, outcomes, and management of specific AEs asso-
ciated with bevacizumab treatment (henceforth referred to as 
“select AEs”), and evaluating the incidence of other serious 
AEs (SAEs) that were not included in the list of select AEs, 
but were suspected by the investigator to be associated with 
the use of bevacizumab.
Data Collection
Patient data were collected prospectively from study 
sites by means of electronic data capture at baseline and sub-
sequently every 3 months until death, withdrawal of consent, 
loss to follow-up, or study closure. Protocol-specified demo-
graphics, disease characteristics, and patient medical history 
data were collected at baseline, including smoking history, use 
of concomitant medications, and history of hemoptysis. Dates 
of actual bevacizumab administration, and chemotherapy plus 
biologic treatment start and stop dates, were also captured.
Baseline radiographic chest scans (computed tomog-
raphy, magnetic resonance imaging, or positron emission 
tomography) were requested from all consenting patients for 
the purposes of enhancing the evaluation of risk factors for 
pulmonary hemorrhage. Scans were reviewed at an indepen-
dent review facility and read according to a separate charter; 
review included the evaluation of characteristics such as tumor 
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and lymph node size, location (central, peripheral), presence 
or absence of cavitation, size of cavitation (if present), and 
vascular involvement. Follow-up scans were collected from 
a subset of 198 patients to examine the association between 
cavitation and the risk of pulmonary hemorrhage.
Sites were asked to report, within 48 hours of their 
knowledge, the following AEs (termed “protocol-specified 
AEs”) occurring up to 90 days after the last bevacizumab 
dose: select AEs, regardless of severity; any AEs that resulted 
in the discontinuation of bevacizumab; and any SAEs sus-
pected to be associated with bevacizumab. Select AEs 
included new or worsening hypertension requiring medica-
tion; severe bleeding events (including pulmonary hemor-
rhage, epistaxis, gastrointestinal bleeding, central nervous 
system [CNS] hemorrhage, and other bleeding events); arte-
rial thromboembolic events (ATEs); venous thromboembolic 
events (VTEs); postoperative wound-bleeding or wound-
healing complications; symptomatic congestive heart fail-
ure; and reversible posterior leukoencephalopathy syndrome, 
regardless of its association with bevacizumab or whether the 
event was considered serious.
Statistical Measures
Kaplan-Meier methods and 95% confidence inter-
vals (CIs) were used to characterize PFS and OS. PFS and 
OS outcomes were measured from the date of the initiation 
of therapy, which was defined as the earlier of first-line che-
motherapy or bevacizumab dosing. PFS was defined as the 
time from the start of therapy to investigator-assessed dis-
ease progression or death from any cause on study. OS was 
defined as the time from the start of therapy to death from any 
cause. Patients without an event (progression or death) were 
censored at the study termination or data cutoff date, which-
ever occurred first. A Cox proportional hazards model was 
used to assess the independent effects of patient and disease 
characteristics on PFS and OS. Additional analyses evaluated 
the effect of sex (male versus female), race (non-white ver-
sus white), ECOG PS (≥2 versus all others), smoking history 
(never versus current/former), adjuvant treatment (yes versus 
no), presence of brain metastases (yes versus no), cardiovas-
cular disease at baseline (yes versus no), history of hemopty-
sis (yes versus no), hypertension at baseline (yes versus no), 
diabetes at baseline (yes versus no), hypercholesterolemia at 
baseline (yes versus no), weight loss of >5% at baseline (yes 
versus no), baseline histology (adenocarcinoma versus non-
adenocarcinoma), measurable disease (yes versus no), and 
disease categorization (locally advanced versus metastatic) on 
survival outcomes.
To examine the potential nonlinear temporal distribu-
tion of safety events, and to account for the variable follow-up 
time on study, risks of AEs were estimated as incidence pro-
portions over the entire follow-up period and by 6-month fol-
low-up intervals. Incidence proportions were calculated from 
the date of the actual first dose of bevacizumab, even if this 
date was earlier than the study enrollment date. For patients 
who started bevacizumab before study enrollment, sites were 
asked to report any AEs that occurred before enrollment while 
on bevacizumab therapy.
RESULTS
Patient and Disease Characteristics at Baseline
ARIES enrolled 1967 patients with previously 
untreated advanced NSCLC from November 2006 to June 
2009 from 248 study sites in 43 US states (Table 1). The 
median age at enrollment was 65 years (range, 31–93). The 
majority of patients were male (53%), white (88%), and had 
an ECOG PS of 0 or 1 (85%). In ARIES, 252 (13%) patients 
identified as never smokers, defined as having smoked a total 
of fewer than 100 cigarettes. Most patients (83%) presented 
with metastatic disease at baseline, and 8% had brain metas-
tases. The majority of the patients had adenocarcinoma his-
tology (69%). At baseline, 7% of patients had a history of 
hemoptysis, 63% had cardiovascular risk factors (i.e., dia-
betes, hypertension requiring medication, hypercholesterol-
emia, and family history of early cardiac death), and 25% had 
more than 5% weight loss within 6 months before beginning 
therapy with bevacizumab. Of the 1290 patients who were 
receiving concomitant medications at enrollment, 79% were 
receiving antihypertensive or cardiovascular medication, and 
50% were receiving cholesterol-lowering therapy. In addi-
tion, 13% (168/1290) of patients were receiving concomitant 
anticoagulation medication (prophylactic, 76 patients; thera-
peutic, 92 patients).
Among the patients with NSCLC enrolled in ARIES, 
1880 patients had baseline scans available, with 1489 
patients having measurable tumors at baseline (see Table 1). 
In patients with measurable tumors, the majority (76%) had 
only one measurable tumor, 49% had at least one centrally 
located tumor at baseline, and 15% had cavitations in their 
baseline measurable tumors. Among patients with cavita-
tions (n = 217), the majority (90%) had only a single cavita-
tion (of any size), and 2% had largest cavitations of ≥4 cm 
in diameter.
Treatment
At the close of the study (March 31, 2012), the median 
follow-up time was 12.5 months (range, 0.2–65.5 months). 
The median duration of cumulative bevacizumab use was 
3.7 months (range, 0.1–49.3 months), and patients received 
a median of six doses of bevacizumab (range, 1–88 doses). 
The median duration of cumulative chemotherapy use was 
7.0 months (range, 0.1–65.6 months), with the most common 
chemotherapy used in combination with bevacizumab being 
carboplatin with paclitaxel (61.7%) (see Table 1). Overall, 
91% of all patients received a platinum-containing chemo-
therapy regimen.
Given that ARIES investigators enrolled patients over 
several years, baseline treatment patterns were examined 
over time. The data suggest that the use of bevacizumab in 
combination with a platinum-containing chemotherapy regi-
men should remain a standard of care in real-world settings; 
however, a small percentage of clinicians used bevacizumab in 
combination with pemetrexed, and the use of this combination 
appears to have increased over time (Fig. 1). The relative num-
ber of patients receiving erlotinib remained fairly constant but 
was low over this period.
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Effectiveness Outcomes
By the close of the study, 1474 patients (74.9%) had 
experienced disease progression and 1723 patients (87.6%) 
had died. Median PFS was 6.6 months (95% CI, 6.3–6.9), 
and median OS was 13.0 months (95% CI, 12.2–13.8) 
(Table 2; Fig. 2).
The multivariable Cox model identified that male sex 
(hazard ratio [HR], 1.10; 95% CI, 1.01–1.21), an ECOG PS 
≥2 (HR, 1.21; 95% CI, 1.06–1.37), cardiovascular disease at 
baseline (HR, 1.11; 95% CI, 1.00–1.24), weight loss of >5% 
at baseline (HR, 1.29; 95% CI, 1.16–1.43), and the presence 
of measurable disease (HR, 1.23; 95% CI, 1.11–1.38) were 
significantly associated with poorer PFS outcomes, whereas 
non-white race (HR, 0.85; 95% CI, 0.73–0.98) and locally 
advanced disease (HR, 0.75; 95% CI, 0.66–0.85) were signifi-
cantly associated with improved PFS.
Histology
  Adenocarcinoma 1363 69.3
  NSCLC, not otherwise specified 394 20
  Large cell carcinoma 87 4.4
  Otherd 123 6.3
Baseline scans available for patients with ≥1 
measurable tumor
1489 75.7
Number of measurable tumors per patient
  1 1124 75.5
  2–4 342 23
  5–10 23 1.5
Size of largest measurable tumor n = 1489
  <3.0 cm 489 32.8
  3.0 to <4.0 cm 310 20.8
  ≥4.0 cm 690 46.3
Presence of ≥1 centrally located tumor n = 1489
  Yes 731 49.1
  No 758 50.9
Presence of cavitation in measurable tumor n = 1489
  Yes 217 14.6
  No 1, 272 85.4
Size of largest cavitation in measurable tumor n = 217
  Too small to measure 69 31.8
  0.5 to <1.0 cm 65 30
  1.0 to <3.0 cm 73 33.6
  ≥3.0 cm 10 4.6
aPatients who have smoked fewer than 100 cigarettes.
bCardiovascular disease includes stroke, transient ischemic attack, myocardial 
infarction, unstable angina, peripheral artery disease, deep vein thrombosis, pulmonary 
emboli, chronic atrial fibrillation, congestive heart failure, and other.
cThose that required drug therapy.
dBaseline chemotherapy regimen groups are not mutually exclusive.
dBronchoalveolar carcinoma, mixed, unknown, and “other.”
ARIES, Avastin Regimens: Investigation of Effectiveness and Safety; CV, 
cardiovascular; ECOG PS, Eastern Cooperative Oncology Group performance status; 
NSCLC, non–small-cell lung cancer.
TABLE 1. (Continued)
All NSCLC  
(N = 1967)
No. %
TABLE 1.  Patient Baseline and Disease Characteristics in 
ARIES NSCLC
All NSCLC  
(N = 1967)
No. %
Disease categorization
  Locally advanced 326 16.6
  Metastatic 1641 83.4
Age
  Median, years (range) 65 (31–93)
  ≥65 1013 51.5
  ≥75 370 18.8
Sex
  Male 1049 53.3
  Female 918 46.7
Race
  White 1731 88
  Black 150 7.6
  Asian or Pacific Islander 32 1.6
  Hispanic 41 2.1
  Other 13 0.7
ECOG PS
  0 709 36
  1 957 48.7
  ≥2 182 9.3
  Unknown 119 6
Smoking status
  Nevera 252 12.8
  Current 484 24.6
  Former 1231 62.6
Prior adjuvant therapy 233 11.8
Presence of brain metastases 150 7.6
History of cardiovascular diseaseb 532 27
History of hemoptysis 141 7.2
Weight loss more than 5% within 6  months before 
initiating bevacizumab
498 25.3
Use of additional concomitant medication n = 1290
  Anticoagulation 168 13
   Prophylactic anticoagulation 76 45.2
   Therapeutic anticoagulation 92 54.8
  Antiplatelet 455 35.3
  Cholesterol-lowering 646 50.1
  Antihypertensive/CV 1016 78.8
Comorbiditiesc
  Hypertension 989 50.3
  Diabetes 252 12.8
  Hypercholesterolemia 639 32.5
Baseline chemotherapy regimensc
  Carboplatin/paclitaxel 1214 61.7
  Carboplatin/non-paclitaxel 474 24.1
  Cisplatin/any 80 4.1
  Gemcitabine/any 252 12.8
  Pemetrexed/any 184 9.4
  Erlotinib/any 67 3.4
(Continued )
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In additional analyses of OS, factors significantly asso-
ciated with shorter OS were male sex (HR, 1.14; 95% CI, 
1.04–1.26), an ECOG PS ≥2 (HR, 1.47; 95% CI, 1.29–1.67), 
cardiovascular disease at baseline (HR, 1.26; 95% CI, 1.13–
1.41), and weight loss of >5% at baseline (HR, 1.40; 95% 
CI, 1.26–1.56). In contrast, hypercholesterolemia at baseline 
(HR, 0.87; 95% CI, 0.78–0.97) and locally advanced disease 
(HR, 0.73; 95% CI, 0.64–0.84) were significantly associated 
with longer OS. The model showed a similar risk for death 
when evaluating other subgroups defined by patient and dis-
ease characteristics.
Safety
In ARIES, the incidence rate for any protocol-spec-
ified AE was 19.7%, and SAEs were observed in 10.9% of 
patients (Table 3). A total of 124 patients (6.3%) temporar-
ily discontinued bevacizumab treatment at least once because 
of bevacizumab-related toxicity, and 269 patients (13.7%) 
permanently discontinued bevacizumab because of an AE. 
Thirty-three patients (1.7%) had an AE resulting in death. 
ATEs and VTEs occurred in 2.2% and 6.1% of patients, 
respectively. Twenty-three patients (1.2%) developed severe 
pulmonary hemorrhage, and three patients (0.2%) had grade 
3 to 5 CNS hemorrhage. In general, a trend was observed for 
bevacizumab-select AEs occurring more frequently in the first 
6 months of bevacizumab therapy than later in the course of 
treatment (see Table 3).
DISCUSSION
As is often the case with a novel therapeutic, the approval 
of bevacizumab for the treatment of NSCLC in combination 
with chemotherapy raised several questions with respect to 
optimal treatment patterns, and its safety and effectiveness, in 
a broader patient population than those enrolled in RCTs.3 The 
ARIES OCS provided a unique opportunity to examine the 
safety and effectiveness of bevacizumab in a large, unselected 
population of patients with locally advanced or metastatic 
NSCLC treated in a real-world setting. In fact, treatment pat-
terns in ARIES generally reflected those found in the general 
population of patients who initiated treatment in the first-line 
setting for NSCLC during a similar time period,11 with pacli-
taxel and carboplatin being the most prevalent backbone che-
motherapy regimen used; the use of pemetrexed as part of a 
combination regimen increased over time.
Although results from observational studies and RCTs 
are not directly comparable, largely due to differing patient 
November 2006 – October 2007
(n = 841)
November 2007 – October 2008
(n = 754)
November 2008 – June 2009
(n = 372)
a  b  c  d  e  f a  b  c  d  e  f a  b  c  d  e  f 
a  Carboplatin/paclitaxel
b  Carboplatin/non-paclitaxel
c  Cisplatin/any
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FIGURE 1.  Baseline chemotherapy 
use by period of study enrollment.
TABLE 2.  Effectiveness Outcomes of Bevacizumab with First-Line Chemotherapy for NSCLC in the ARIES OCS, the Phase IV 
SAiL Study, and the Phase III Clinical Trials E4599 and AVAiL
ARIES NSCLC  
(n = 1967)
SAiL7  
(n = 2212)
E45992  
(n = 434 ITT)
AVAiL4,5 7.5 mg/kg
(n = 345 ITT)
(n = 307 PP)
AVAiL4,5 15 mg/kg
(n = 351 ITT)
(n = 285 PP)
Chemotherapy Regimen Investigator’s choice Investigator’s choice Paclitaxel + carboplatin Gemcitabine + cisplatin Gemcitabine + cisplatin
Median follow-up,  
months (range)
12.5 (0.2–65.5) 12.5 (SD, 7.1–12.5) 19 (for n = 851) ≥7 for PFS
≥12.5 for OS
≥7 for PFS
≥12.5 for OS
Median PFS,  
months (95% CI)
6.6 (6.3–6.9) 7.8 (7.5–8.1)a 6.2 (range N/A) 6.7 (range N/A) 6.5 (range N/A)
Median OS,  
months (95% CI)
13.0 (12.2–13.8) 14.6 (13.8–15.3) 12.3 (11.3–13.7) 13.6 (11.8−15.8) 13.4 (11.1–15.1)
ORRb (%) 49.0 51.5 34.9 37.8 34.6
aThe SAiL study reported time to progression (TTP) outcomes instead of PFS.
bPatients experiencing a complete response or a partial response; responses were assessed by investigators in ARIES.
ARIES, Avastin Regimens: Investigation of Effectiveness and Safety; AVAiL, Avastin in Lung; CI, confidence interval; E4599, Eastern Cooperative Oncology Group 4599; ITT, 
intent-to-treat; N/A, not available; NSCLC, non–small-cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PP, per protocol.
1337Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014 Results from the ARIES NSCLC Observational Study
exclusions, patients being randomized to treatment, and pro-
tocol-mandated treatment in RCTs,10 the outcomes observed 
in ARIES, which included a greater diversity of patients, are 
consistent with those of RCTs investigating bevacizumab 
in combination with chemotherapy in the first-line setting. 
Median PFS and OS results were similar between ARIES and 
the E4599 trial of bevacizumab with paclitaxel + carboplatin, 
and the AVAiL study of bevacizumab with cisplatin + gem-
citabine (see Table 2).2,4,5
Results in ARIES were also comparable with results 
reported by the large phase IV SAiL study, which was con-
ducted primarily in Europe from 2006 to 2008 and simi-
larly left the choice of chemotherapy regimen and dose of 
bevacizumab to the treating physician.7 SAiL reported a 
median OS of 14.6 months (95% CI, 13.8–15.3), which was 
longer than the median OS time observed in ARIES (median 
OS, 13.0 months; 95% CI, 12.2–13.8). However, there were 
important differences between the phase IV SAiL study and 
the ARIES OCS, including the fact that ARIES reported PFS 
outcomes, whereas SAiL only reported time to progression 
outcomes. The patient population of the SAiL study included 
patients who were generally younger and healthier compared 
with patients in ARIES.7 In addition, the SAiL study specified 
that bevacizumab was to be administered with chemotherapy 
for a maximum of six 3-week cycles at 7.5 or 15 mg/kg, after 
which bevacizumab was to be continued as a single-agent 
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FIGURE 2.  Kaplan-Meier curves 
of (A) progression-free survival and 
(B) overall survival in non–small-cell 
lung cancer patients in the ARIES 
(Avastin Regimens: Investigation of 
Effectiveness and Safety) trial.
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TABLE 3.  Bevacizumab-Select Grade ≥3 Adverse Events in ARIES NSCLC
Adverse Event
Any Time Months 0 to <6 Months 6 to <12 Months ≥12
No. % No. % No. % No. %
Protocol-specified AEs 387 19.7 284 14.4 67 6.4 36 9.2
Serious AEs 214 10.9 N/A N/A N/A N/A N/A N/A
GI perforation 22 1.1 15 0.8 4 0.3 3 0.7
POWBHC 1 0.1 1 0.6 0 0.0 0 0.0
ATEs 43 2.2 27 1.4 8 0.7 8 1.8
VTEs 120 6.1 89 4.5 22 2.0 9 2.1
RPLS 3 0.2 2 0.1 1 0.1 0 0.0
Hypertension requiring medical management 86 4.4 67 3.4 13 1.2 6 1.4
Congestive heart failure 6 0.3 3 0.2 2 0.2 1 0.2
All grade 3–5 bleeding events 80 4.1 62 3.2 12 1.0 6 1.3
  Severe PH 23 1.2 19 1.0 3 0.3 1 0.2
  Grade 3–5 CNS hemorrhage 3 0.2 3 0.2 0 0.0 0 0.0
  Grade 3–5 epistaxis 10 0.5 6 0.3 3 0.3 1 0.2
  Grade 3–5 GI bleeding 31 1.6 22 1.1 5 0.4 4 0.9
  Grade 3–5 other bleeding events 15 0.8 13 0.7 1 0.1 1 0.2
  Grade 3–5 bleeding other than PH 57 2.9 43 2.2 9 0.8 5 1.1
Non-severe PH 7 0.4 5 0.3 2 0.2 0 0.0
All bleeding (grade 3–5 and grade 2 PH) 86 4.4 66 3.4 14 1.2 6 1.4
Other AEs/SAEs 67 3.4 46 2.3 13 1.1 8 1.8
AE, adverse event; ARIES, Avastin Regimens: Investigation of Effectiveness and Safety; ATE, arterial thromboembolic event; CNS, central nervous system; GI, gastrointestinal; 
N/A, not available; NSCLC, non–small-cell lung cancer; PH, pulmonary hemorrhage; POWBHC, postoperative wound-bleeding or wound-healing complication; RPLS, reversible 
posterior leukoencephalopathy syndrome; SAE, serious adverse event; VTE, venous thromboembolic event.
TABLE 4.  Safety Outcomes in Clinical Trials of Bevacizumab with First-Line Chemotherapy for NSCLCa
Patients with at  
least one AE, n (%)
ARIES NSCLC  
(N = 1967)
E4599b  
(N = 427)
AVAiL 7.5 mg/kgb  
(N = 330)
AVAiL 15 mg/kgb  
(N = 329)
No. % No. % No. % No. %
Overall AEs
  Any ARIES protocol-specified AEsc 387 19.7 – – – – – –
  Any ARIES protocol-specified SAEs 214 10.9 – – – – – –
ARIES protocol-specified AEsc
  Hypertension requiring medical 
management
86 4.4 33d 7.7 21 6 29 9
  ATEs 43 2.2 12 2.8 8 2 10 3
  VTEs 120 6.1 24 5.6 24 7 23 7
  All grade 3–5 bleeding events
   Severe PH
80
23
4.1
1.2
20
10
4.7
2.3
14
5
  4
1.5
16
3
    5
0.9
  GI perforation 22 1.1 4 0.9 0 0 1 <1
  Congestive heart failure 6 0.3 3 0.7 4 1 4 <1
  POWBHC 1 0.1 N/A N/A 0 0.0 0 0.0
  RPLS 3 0.2 N/A N/A N/A N/A N/A N/A
  Other AEs/SAEs 67 3.4 – – – – – –
aDifferent definitions for individual AEs may have been used in different studies. ARIES used prespecified terms on the case report form as listed in the table and were not 
subsequently coded using standardized definitions. The E4599 study used the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 2.0, definitions for 
coding AEs reported on the case report forms, and AVAiL used the Medical Dictionary for Regulatory Activities (MedDRA) definitions for coding AEs reported on the case report forms.
bGrades 3–5 AEs only.
cNumbers in specific subtypes of events may not add up to the higher category because patients may have had more than one subtype of AE.
dThis number comprises 31 cases of grade 3 and two cases of grade 4 events.
AE, adverse event; ARIES, Avastin Regimens: Investigation of Effectiveness and Safety; ATE, arterial thromboembolic event; AVAiL, Avastin in Lung; E4599, Eastern Cooperative 
Oncology Group 4599 study; GI, gastrointestinal; N/A, not available; NSCLC, non–small-cell lung cancer; PH, pulmonary hemorrhage; POWBHC, postoperative wound-bleeding or 
wound-healing complication; RPLS, reversible posterior leukoencephalopathy syndrome; SAE, serious adverse event; VTE, venous thromboembolic event.
1339Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014 Results from the ARIES NSCLC Observational Study
until disease progression. The ARIES study placed no such 
restrictions on the dose or administration of bevacizumab. 
Lastly, bevacizumab was provided to patients enrolled in the 
SAiL study; in ARIES, no medical care or treatments were 
provided by the study sponsor. Although the results of these 
two noncomparative studies were similar, the differences 
between the design of the two studies and in the enrolled 
patient populations further broadened the clinical understand-
ing of bevacizumab safety and effectiveness in less-selected 
patient populations compared with RCTs.
Grade ≥3 bevacizumab-associated AEs, including 
hypertension, bleeding events, and VTEs occurred at rates 
similar to those reported in E4599 and AVAiL (Table 4).2,4 
However, the method by which AEs were collected in ARIES 
prohibits direct comparison of safety results reported by 
RCTs. In particular, ARIES did not collect data on all AEs; 
rather, information on grade ≥3 bevacizumab-select AEs 
(as defined in the study protocol) occurring fewer than 90 
days after the last dose of bevacizumab was exclusively col-
lected. Furthermore, data on proteinuria, a common beva-
cizumab-associated toxicity that is frequently a cause for 
treatment discontinuation, were not collected in ARIES. In 
ARIES, the timing of the onset of AEs was examined, and 
many events were found to be more likely to occur within 
the first 6 months of initiation of bevacizumab treatment. 
This is consistent with a previous report that suggested that 
AEs related to bevacizumab treatment are more likely to 
occur early in treatment.12
Limitations of the ARIES study, like all OCSs, include 
potential biases related to data entry and reporting errors, 
missing data, and unmeasured confounding bias.13 Although 
steps were taken during the design of the study to limit selec-
tion bias (i.e., study centers were encouraged to enroll all eli-
gible patients), it is still possible that unintended selection bias 
occurred. To reduce errors in data entry and reporting, a clini-
cal review of the data occurred every 6 months throughout the 
course of the study. Confounding bias was potentially reduced 
by collecting and adjusting all analyses for known or potential 
strong confounders.
In summary, as observed in the ARIES OCS, the real-
world experience with bevacizumab shows that patients are 
receiving bevacizumab in combination with a broad range of 
first-line treatment regimens and that safety and effectiveness 
for patients with locally advanced or metastatic NSCLC is 
comparable to that shown in RCTs. In this large, less-rigor-
ously selected patient population than is often found in RCTs, 
the outcomes reported add further evidence of the overall 
safety and effectiveness profile of bevacizumab-containing 
treatment and support the use of bevacizumab in clinical prac-
tice as deemed appropriate by treating physicians.
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